Abou-Alfa GK et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. ASCO 2022;Abstract 379.
Abou-Alfa GK et al. Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma (CCA): Update of FIGHT-202. ASCO 2021;Abstract 4086.
Abou-Alfa GK et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. N Eng J Med Evid 2022. Abstract
Bekaii-Saab TS et al. KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation. ASCO 2022;Abstract 519.
Bibeau K et al. Progression-free survival in patients with cholangiocarcinoma with or without FGF/FGFR alterations: A FIGHT-202 post hoc analysis of prior systemic therapy response. J Clin Oncol Precis Oncol 2022;6:e2100414. Abstract
Cheng A-L et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol 2022;76(4):862-73. Abstract
Galle PR, Abou-Alfa GK. Decision making in systemic therapy for hepatocellular carcinoma: Should we pay attention to disease aetiology? J Hepatol 2021;75(4):763-4. Abstract
Goyal L et al. Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements. ASCO 2022;Abstract 4009.
Harding J et al. Nivolumab (NIVO) and drug eluting bead transarterial chemoembolization (deb-TACE): Updated results from an ongoing phase 1 study of patients (pts) with liver limited hepatocellular carcinoma (HCC). ASCO GI 2022;Abstract 437.
Hilal L et al. Ablavtive radiation therapy for hepatocellular carcinoma is associated with reduced treatment- and tumor-related liver failure and improved survival. J Gastrointest Oncol 2021;12(4):1743-52. Abstract
Javle M et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: Mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Cantroenterol Hepatol 2021;6(10):803-15. Abstract
Javle M et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): A multicenter, open-label, phase 2a, multiple basket study. Lancet Oncol 2021;22(9):1290-300. Abstract
Kelley RK et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2022;[Online ahead of print]. Abstract
Kelley RK et al. Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: Randomized expansion of a phase I/II study. J Clin Oncol 2021;39(27):2991-3001.Abstract
Kolamunnage-Dona R et al. Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma. J Hepatol 2021;75(4):876-87. Abstract
Kundra R et al. OncoTree: A cancer classification system for precision oncology. J Clin Oncol Clin Cancer Inform 2021;5:221-30. Abstract
Lee TY et al. Equipoise, drug development, and biliary cancer. Cancer 2022;128(5):944-9. Abstract
Lim YH et al. Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from the Phase 2 study 22 (NCT02519348). Gastrointestinal Cancers Symposium 2022;Abstract 436.
Lin N et al. A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinoma. Hepatol Commun 2022;6(7):1753-63. Abstract
McCoon P et al. T-cell receptor pharmacodynamics associated with survival and response to tremelimumab (T) in combination with durvalumab (D) in patients (pts) with unresectable hepatocellular carcinoma (uHCC). ASCO 2022;Abstract 4087.
Meric-Bernstam F et al. Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I Study. Gastrointestinal Cancers Symposium 2021;Abstract 299.
Mondaca S et al. Clinical and genomic characterization of ERBB2-altered gallbladder cancer. ASCO 2022;Abstract 4114.
Oh D-Y et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. N Eng J Med Evid 2022. Abstract
Ohba A et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial). ASCO 2022;Abstract 4006.
Park W et al. Immunogenomic characterization of biliary tract cancers: Biomarker enrichment for benefit to immune checkpoint blockade. ASCO 2022;Abstract 4083.
Qin S et al. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma: Phase 3 KEYNOTE-394 study. Gastrointestinal Cancers Symposium 2022;Abstract 383.
Ren Z et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): A randomised, open-label, phase 2-3 study. Lancet Oncol 2021;22(7):977-90. Abstract
Sangro B et al. A phase 3, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC). Gastrointestinal Cancers Symposium 2021;Abstract TPS349.
Sangro B et al. Patient-reported outcomes from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. ASCO 2022;Abstract 4074.
Segal NH et al. Phase II single-arm study of durvalumab and tremelimumab with concurrent radiotherapy in patients with mismatched repair-proficient metastatic colorectal cancer. Clin Cancer Res 2021;27(8):2200-8. Abstract
Song X et al. Exposure-response (E-R) efficacy and safety (E-S) analyses of tremelimumab as monotherapy or in combination with durvalumab in patients (pts) with unresectable hepatocellular carcinoma (uHCC). Gastrointestinal Cancers Symposium 2021;Abstract 313.
Subbiah V et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): A phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol 2020;21(9):1234-43. Abstract
Valle JW et al. Biliary tract cancer. Lancet 2021;397(10272):428-44. Abstract
Yau T et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The CheckMate 040 randomized clinical trial. JAMA Oncol 2020;6(11):e204564. Abstract
Yau T et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): A randomized, multicentre, open-label, phase 3 trial. Lancet Oncol 2022;23(1):77-90. Abstract
Zhu AX et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: The phase 3 randomized clinical ClarIDHy trial. JAMA Oncol 2021;7(11):1669-77. Abstract